Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial

Rainer Zbinden, Raffaele Piccolo, Dik Heg, Marco Roffi, David J Kurz, Olivier Muller, André Vuilliomenet, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Anna Franzone, Franz Eberli, Peter Jüni, Stephan Windecker, Thomas Pilgrim, Rainer Zbinden, Raffaele Piccolo, Dik Heg, Marco Roffi, David J Kurz, Olivier Muller, André Vuilliomenet, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Anna Franzone, Franz Eberli, Peter Jüni, Stephan Windecker, Thomas Pilgrim

Abstract

Background: No data are available on the long-term performance of ultrathin strut biodegradable polymer sirolimus-eluting stents (BP-SES). We reported 2-year clinical outcomes of the BIOSCIENCE (Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularisation) trial, which compared BP-SES with durable-polymer everolimus-eluting stents (DP-EES) in patients undergoing percutaneous coronary intervention.

Methods and results: A total of 2119 patients with minimal exclusion criteria were assigned to treatment with BP-SES (n=1063) or DP-EES (n=1056). Follow-up at 2 years was available for 2048 patients (97%). The primary end point was target-lesion failure, a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. At 2 years, target-lesion failure occurred in 107 patients (10.5%) in the BP-SES arm and 107 patients (10.4%) in the DP-EES arm (risk ratio [RR] 1.00, 95% CI 0.77-1.31, P=0.979). There were no significant differences between BP-SES and DP-EES with respect to cardiac death (RR 1.01, 95% CI 0.62-1.63, P=0.984), target-vessel myocardial infarction (RR 0.91, 95% CI 0.60-1.39, P=0.669), target-lesion revascularization (RR 1.17, 95% CI 0.81-1.71, P=0.403), and definite stent thrombosis (RR 1.38, 95% CI 0.56-3.44, P=0.485). There were 2 cases (0.2%) of definite very late stent thrombosis in the BP-SES arm and 4 cases (0.4%) in the DP-EES arm (P=0.423). In the prespecified subgroup of patients with ST-segment elevation myocardial infarction, BP-SES was associated with a lower risk of target-lesion failure compared with DP-EES (RR 0.48, 95% CI 0.23-0.99, P=0.043, Pinteraction=0.026).

Conclusions: Comparable safety and efficacy profiles of BP-SES and DP-EES were maintained throughout 2 years of follow-up.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01443104.

Keywords: biodegradable polymer; drug‐eluting stent; everolimus‐eluting stent; percutaneous coronary intervention; sirolimus‐eluting stent.

© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Figures

Figure 1
Figure 1
Patient flow according to the CONSORT statement. BMS indicates bare‐metal stent; BP‐SES, biodegradable‐polymer sirolimus‐eluting stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stent; DP‐EES, durable‐polymer everolimus‐eluting stent; PCI, percutaneous coronary intervention.
Figure 2
Figure 2
Kaplan‐Meier curves for the primary end point (panel A) and its compenents (panels B‐D) at 2‐year follow‐up. The blue line shows the BP‐SES, and the red line shows the DP‐EES. BP‐SES indicates biodegradable‐polymer sirolimus‐eluting stent; DP‐EES, durable‐polymer everolimus‐eluting stent; RR, risk ratio; TLR, target‐lesion revascularization.
Figure 3
Figure 3
Kaplan–Meier curves for the landmark analyses of the primary end point and its components. The blue line shows the BP‐SES, and the red line shows the DP‐EES. TLR indicates target‐lesion revascularization; TV, target vessel.
Figure 4
Figure 4
Stratified analysis of target‐lesion failure at 2 years across prespecified subgroups. Number of first events and percentages are reported. Rate ratios with 95% CIs are estimated using the Mantel–Cox method with 2‐sided P values from log‐rank test. Renal failure indicates a creatinine‐estimated glomerular filtration rate of <60 mL/min using the Modification of Diet in Renal Disease formula. BMI indicates body mass index; BP‐SES, biodegradable‐polymer sirolimus‐eluting stent; DP‐EES, durable‐polymer everolimus‐eluting stent.

References

    1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
    1. Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. Lancet. 2015;386:702–713.
    1. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116:1952–1965.
    1. Stefanini GG, Holmes DR Jr. Drug‐eluting coronary‐artery stents. N Engl J Med. 2013;368:254–265.
    1. Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blochlinger S, Heg D, Juni P, Windecker S. Safety and efficacy of resolute zotarolimus‐eluting stents compared with everolimus‐eluting stents: a meta‐analysis. Circ Cardiovasc Interv. 2015;8:e002223.
    1. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Juni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta‐analysis. BMJ. 2014;348:g3859.
    1. Pilgrim T, Heg D, Roffi M, Tuller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Juni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus‐eluting stent versus durable polymer everolimus‐eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single‐blind, non‐inferiority trial. Lancet. 2014;384:2111–2122.
    1. Pilgrim T, Roffi M, Tuller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Heg D, Juni P, Windecker S. Randomized comparison of biodegradable polymer sirolimus‐eluting stents versus durable polymer everolimus‐eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. Am Heart J. 2014;168:256–261.
    1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research C . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351.
    1. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker‐Havinga T, van Es GA, Meier B, Juni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer‐based biolimus‐eluting stents versus durable polymer‐based sirolimus‐eluting stents in patients with coronary artery disease: final 5‐year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777–789.
    1. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; Investigators N . Biodegradable polymer biolimus‐eluting stent versus durable polymer everolimus‐eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62:181–190.
    1. Danzi GB, Piccolo R, Galasso G, Piscione F. Nobori biolimus‐eluting stent vs. permanent polymer drug‐eluting stents in patients undergoing percutaneous coronary intervention. Circ J. 2014;78:1858–1866.
    1. Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vazquez N, Valdes M, Voudris V, Puricel S, Slagboom T, Goy JJ, den Heijer P, van der Ent M. Long‐term clinical outcomes of biodegradable polymer biolimus‐eluting stents versus durable polymer everolimus‐eluting stents in patients with coronary artery disease: three‐year follow‐up of the COMPARE II (Abluminal biodegradable polymer biolimus‐eluting stent versus durable polymer everolimus‐eluting stent) trial. EuroIntervention. 2015;11:272–279.
    1. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T. Final 3‐year outcome of a randomized trial comparing second‐generation drug‐eluting stents using either biodegradable polymer or durable polymer: NOBORI Biolimus‐Eluting Versus XIENCE/PROMUS Everolimus‐Eluting Stent Trial. Circ Cardiovasc Interv. 2015;8:e002817 doi: .
    1. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta‐analysis. BMJ. 2013;347:f6530.
    1. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable‐polymer drug‐eluting stents vs. bare metal stents vs. durable‐polymer drug‐eluting stents: a systematic review and Bayesian approach network meta‐analysis. Eur Heart J. 2014;35:1147–1158.
    1. Piccolo R, Nicolino A, Danzi GB. The Nobori biolimus‐eluting stent: update of available evidence. Expert Rev Med Devices. 2014;11:275–282.
    1. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen‐Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high‐risk interventional settings is driven by stent design and deployment and protected by polymer‐drug coatings. Circulation. 2011;123:1400–1409.
    1. Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krussel L, Tilsted H, Junker A, Terkelsen CJ, Vein KT, Kaltoft A, Villadsen AB, Aaroe J, Berencsi K, Jensen SE, Hansen KN, Kristensen SD, Madsen M, Botker HE, Hansen HS, Raungaard B, Lassen JF, Christiansen EH. Randomised comparison of a sirolimus‐eluting stent with a biolimus‐eluting stent in patients treated with PCI: the SORT OUT VII trial. Presented at EuroPCR 2015, Paris. 2015. Available at: . Accessed November 30, 2015.
    1. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta‐analysis. BMJ. 2013;347:f6625.
    1. Windecker S, Haude M, Neumann FJ, Stangl K, Witzenbichler B, Slagboom T, Sabate M, Goicolea J, Barragan P, Cook S, Piot C, Richardt G, Merkely B, Schneider H, Bilger J, Erne P, Waksman R, Zaugg S, Juni P, Lefevre T. Comparison of a novel biodegradable polymer sirolimus‐eluting stent with a durable polymer everolimus‐eluting stent: results of the randomized BIOFLOW‐II trial. Circ Cardiovasc Interv. 2015;8:e001441 doi: .
    1. Saito S, Valdes‐Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; Investigators CI . A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus‐eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug‐Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J. 2014;35:2021–2031.
    1. Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD. Efficacy and safety of a novel bioabsorbable polymer‐coated, everolimus‐eluting coronary stent: the EVOLVE II Randomized Trial. Circ Cardiovasc Interv. 2015;8:e002372 doi: .
    1. Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab AA, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S. Biodegradable polymer sirolimus‐eluting stents versus durable polymer everolimus‐eluting stents for primary percutaneous coronary revascularization of acute myocardial infarction. EuroIntervention. 2015;11(8).
    1. Piccolo R, Cassese S, Galasso G, Niglio T, De Rosa R, De Biase C, Piscione F. Long‐term clinical outcomes following sirolimus‐eluting stent implantation in patients with acute myocardial infarction. A meta‐analysis of randomized trials. Clin Res Cardiol. 2012;101:885–893.
    1. Piscione F, Piccolo R, Cassese S, Galasso G, Chiariello M. Clinical impact of sirolimus‐eluting stent in ST‐segment elevation myocardial infarction: a meta‐analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2009;74:323–332.
    1. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus‐eluting stent with biodegradable polymer versus sirolimus‐eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non‐inferiority trial. Lancet. 2008;372:1163–1173.
    1. de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Juni P, Kastrati A, Windecker S. Long‐term outcomes of biodegradable versus durable polymer drug‐eluting stents in patients with acute ST‐segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. EuroIntervention. 2015;10:1425–1431.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir